Episode 269: ESMO 2023: Antibody Drug Conjugate Doublets in UC

Brad McGregor, MD joins the podcast to discuss results from the phase 1 double antibody-drug conjugate (DAD) trial on the safety and efficacy of sacituzumab govitecan plus enfortumab vedotin as a second-line or higher therapy for metastatic urothelial carcinoma.

Dr. McGregor is a medical oncologist at Dana-Farber Cancer Institute and is Director of Clinical Research at the Lank Center for Genitourinary Oncology.